Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?

Core Viewpoint - Pfizer has been a disappointing stock in recent years, with a 38% decline over the past three years, primarily due to concerns about growth and upcoming patent expirations [1] Dividend Appeal - Pfizer offers a dividend yield of 6.3%, significantly higher than the S&P 500 average of 1.1%, making it an attractive option for income investors [2] - The sustainability of Pfizer's high dividend is questioned, especially since its diluted earnings per share for the year were $1.36, below the annual dividend payout of $1.72 [3][4] Earnings Forecast - For 2026, Pfizer projects adjusted per-share earnings to be between $2.80 and $3.00, suggesting potential safety for the dividend despite current concerns [5] Revenue and Growth Prospects - Pfizer's revenue declined by 2% in the past year, with modest expectations for improvement by 2026; however, the company has made investments and acquisitions that may enhance future growth [6] - The stock has seen a 6% increase over the past 12 months, indicating that it may be less vulnerable to further declines due to its lower valuation [7]